Novartis AG :Us Fda Approves Expanded Indication For Novartis Leqvio® (Inclisiran) To Include Treatment Of Adults With High Ldl-C And Who Are At Increased Risk Of Heart Disease.Novartis Ag - Label Update Reinforces Robust Safety And Effectiveness Data For Leqvio.Novartis Ag - In Label Update, Safety Section Was Streamlined To Remove Four Adverse Events Since Frequency Of These Events Were Same As Placebo Arm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments